IN2012DN05169A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05169A
IN2012DN05169A IN5169DEN2012A IN2012DN05169A IN 2012DN05169 A IN2012DN05169 A IN 2012DN05169A IN 5169DEN2012 A IN5169DEN2012 A IN 5169DEN2012A IN 2012DN05169 A IN2012DN05169 A IN 2012DN05169A
Authority
IN
India
Prior art keywords
serum half
glycovariant
introducing
increasing
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Seehra Jasbir
Knopf John
Kumar Ravindra
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of IN2012DN05169A publication Critical patent/IN2012DN05169A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
IN5169DEN2012 2009-12-02 2010-12-02 IN2012DN05169A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26609509P 2009-12-02 2009-12-02
US32758210P 2010-04-23 2010-04-23
PCT/US2010/058765 WO2011068993A1 (en) 2009-12-02 2010-12-02 Compositions and methods for increasing serum half-life of fc fusion proteins.

Publications (1)

Publication Number Publication Date
IN2012DN05169A true IN2012DN05169A (zh) 2015-10-23

Family

ID=44115295

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5169DEN2012 IN2012DN05169A (zh) 2009-12-02 2010-12-02

Country Status (11)

Country Link
US (2) US8722615B2 (zh)
EP (1) EP2507267B1 (zh)
JP (1) JP2013512674A (zh)
KR (1) KR20140015152A (zh)
CN (1) CN102770458A (zh)
AU (1) AU2010325943A1 (zh)
BR (1) BR112012013330A2 (zh)
CA (1) CA2782320A1 (zh)
IN (1) IN2012DN05169A (zh)
RU (1) RU2012127383A (zh)
WO (1) WO2011068993A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
US8722615B2 (en) 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
WO2012170938A1 (en) * 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
DK2875045T3 (en) * 2012-07-18 2018-07-02 Apogenix Ag COMPOSITION comprising a mixture of CD95-FC ISOFORMs
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US20160024179A1 (en) * 2013-03-15 2016-01-28 Pyranose Biotherapeutics, Inc. Modified fc fusion proteins
GB201316592D0 (en) * 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
SI3063275T1 (sl) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
WO2015114150A1 (en) * 2014-02-02 2015-08-06 Medimmune Limited Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
AU2015237176A1 (en) * 2014-03-28 2016-10-20 New York University FGF23 fusion proteins
CN105273087A (zh) * 2014-07-14 2016-01-27 复旦大学 NGF-Fc融合蛋白及其制备方法
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
KR20170129233A (ko) 2015-03-26 2017-11-24 악셀레론 파마 인코포레이티드 폴리스타틴-관련된 융합 단백질 및 이들의 용도
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
WO2017023855A1 (en) * 2015-07-31 2017-02-09 The General Hospital Corporation Protein prostheses for mitochondrial diseases or conditions
WO2017083525A1 (en) * 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
US20190241878A1 (en) 2016-07-01 2019-08-08 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
MX2020002070A (es) 2017-08-22 2020-03-24 Sanabio Llc Receptores solubles de interferon y usos de los mismos.
JP2021535746A (ja) * 2018-09-05 2021-12-23 エルジー・ケム・リミテッド Ｏ−グリコシル化可能なポリペプチド領域を含む融合ポリペプチド
KR20210113261A (ko) 2019-01-04 2021-09-15 리졸브 테라퓨틱스, 엘엘씨 뉴클레아제 융합 단백질을 사용한 쇼그렌병의 치료
CA3165342A1 (en) 2020-06-29 2022-01-06 James Arthur Posada Treatment of sjogren's syndrome with nuclease fusion proteins

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
DK0417563T3 (da) * 1989-09-12 2000-11-06 Hoffmann La Roche TNF-bindende proteiner
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
JP3122139B2 (ja) 1991-10-15 2001-01-09 マラーキー，ミッシェル，エフ． 後期段階炎症反応の治療用組成物
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5869337A (en) * 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) * 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
AU2207195A (en) * 1994-04-05 1995-10-23 Board Of Regents, The University Of Texas System Modified receptors that continuously signal
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US7094564B1 (en) * 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1996034095A1 (en) 1995-04-27 1996-10-31 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
US7070783B1 (en) * 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US5817789A (en) * 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US5570401A (en) * 1995-09-22 1996-10-29 General Electric Company BWR containment configuration having partitioned wetwell airspace
EP0942740B1 (en) * 1996-12-06 2003-08-27 Amgen Inc., Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US6548644B1 (en) * 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6265535B1 (en) * 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
AU9222698A (en) 1997-09-05 1999-03-22 Millennium Biotherapeutics, Inc. Novel molecules of the tnfr-ligand-related protein family and uses thereof
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
US6419919B2 (en) * 1997-11-07 2002-07-16 John D. Mountz Method for the augmentation of gene expression
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
CA2321105A1 (en) 1998-02-17 1999-08-19 Incyte Pharmaceuticals, Inc. Human short-chain tnf-receptor family protein
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
WO1999045009A1 (en) * 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
CA2325022A1 (en) * 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
SE9803710L (sv) * 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
WO2000023471A2 (en) * 1998-10-20 2000-04-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of a cytokine-producing lactococcus strain to treat colitis
WO2000025780A1 (en) * 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
AU2000236029A1 (en) 1999-02-23 2000-09-14 Anne Chew Receptor isogenes: polymorphisms in the tissue necrosis factor receptor
US20030148955A1 (en) * 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
AU5636900A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
ES2274378T3 (es) * 1999-08-10 2007-05-16 Glaxo Group Limited Ligando del receptor ep4 y uso contra dolor neuropatico, cancer de colon,hiv y migraña.
DK1210411T3 (da) * 1999-08-25 2007-02-19 Immunex Corp Sammensætninger og fremgangsmåder til forbedret celledyrkning
GB9927681D0 (en) 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
AU3695801A (en) 2000-02-11 2001-11-20 Amgen, Inc. Receptor from tnf family
JP5179689B2 (ja) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
AU4541101A (en) * 2000-03-02 2001-09-12 Xencor Inc Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
EP1265630B1 (en) * 2000-03-24 2006-06-07 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
US6800300B1 (en) * 2000-03-31 2004-10-05 Vasogen Ireland Limited Method for treating autoimmune and alloimmune diseases
WO2002000879A2 (en) 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
WO2002020762A2 (en) 2000-09-05 2002-03-14 Amgen Inc. Tnf receptor-like molecules and uses thereof
US6610750B1 (en) * 2000-09-15 2003-08-26 Laboratoires Negma Treatment of osteoarthritis
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US20020150582A1 (en) * 2001-02-08 2002-10-17 Friedrichs Gregory S. Method of treating or inhibiting cellular injury or cell death
HUP0303246A2 (hu) * 2001-02-23 2003-12-29 Immunex Corporation Aktív fehérjék fokozott kinyerése
US6972327B1 (en) * 2001-05-08 2005-12-06 Immunex Corporation Regeneration of chromatography material
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
ES2516041T3 (es) * 2001-10-10 2014-10-30 Ratiopharm Gmbh Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH)
KR20050042062A (ko) * 2001-11-07 2005-05-04 에프. 호프만-라 로슈 아게 아미노피리미딘 및 피리딘
MXPA04006053A (es) * 2001-12-21 2005-03-31 Immunex Corp Metodos para purificacion de proteina.
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
PL215168B1 (pl) * 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
DE10209821A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
AU2003220529B2 (en) * 2002-03-27 2006-09-07 Immunex Corporation Methods for increasing polypeptide production
US6974681B1 (en) * 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
US6924124B1 (en) * 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US7067279B1 (en) * 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
SI1572744T1 (sl) 2002-12-16 2010-09-30 Genentech Inc Imunoglobulinske variante in njihove uporabe
EP1613261A4 (en) 2003-04-09 2011-01-26 Novo Nordisk As INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
WO2004113387A2 (en) 2003-06-24 2004-12-29 Merck Patent Gmbh Tumour necrosis factor receptor molecules with reduced immunogenicity
EP1654281A1 (en) * 2003-08-01 2006-05-10 Amgen, Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
EP1654004A2 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
US7268116B2 (en) * 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
KR20050082389A (ko) 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
US7507745B2 (en) 2004-02-20 2009-03-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
CA2571781C (en) 2004-06-28 2015-05-12 Yeda Research And Development Co. Ltd Chimeric proteins and uses thereof
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US20090232808A1 (en) 2005-01-28 2009-09-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
WO2006083869A2 (en) 2005-01-31 2006-08-10 Ception Therapeutics, Inc. Tumor necrosis factor inhibitors
US7956160B2 (en) * 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
CN1954882A (zh) 2005-10-14 2007-05-02 李海 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途
US7626895B2 (en) * 2005-12-01 2009-12-01 International Business Machines Corporation Removable media battery pack for powering a media accessor of an automated data-storage library
AU2007309650A1 (en) 2006-02-08 2008-05-02 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100056428A1 (en) 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
IL182956A0 (en) 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
WO2008145139A1 (en) 2007-05-31 2008-12-04 Genmab A/S Fusion or linked proteins with extended half life
CN101778937A (zh) 2007-06-04 2010-07-14 诺和诺德公司 使用n-乙酰葡糖胺转移酶的o-联糖基化
BRPI0814465B1 (pt) 2007-07-26 2021-11-23 Novagen Holding Corporation Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
MX349306B (es) * 2007-09-21 2017-07-19 Univ California Interferón de objetivo demuestra actividades potentes apoptóticas y antitumorales.
EP2242505A4 (en) 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
LT3494986T (lt) * 2008-08-14 2020-07-10 Acceleron Pharma Inc. Gdf gaudyklės
WO2010033854A2 (en) 2008-09-19 2010-03-25 Synageva Biopharma Corp. Avian derived fusion proteins
US8178488B2 (en) * 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
KR20190090049A (ko) * 2009-06-12 2019-07-31 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
US8722615B2 (en) 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life

Also Published As

Publication number Publication date
WO2011068993A1 (en) 2011-06-09
US8722615B2 (en) 2014-05-13
EP2507267B1 (en) 2016-09-14
EP2507267A1 (en) 2012-10-10
EP2507267A4 (en) 2013-05-29
AU2010325943A1 (en) 2012-06-21
CN102770458A (zh) 2012-11-07
US20110171218A1 (en) 2011-07-14
KR20140015152A (ko) 2014-02-06
US20150010555A1 (en) 2015-01-08
JP2013512674A (ja) 2013-04-18
BR112012013330A2 (pt) 2017-03-28
CA2782320A1 (en) 2011-06-09
RU2012127383A (ru) 2014-01-10

Similar Documents

Publication Publication Date Title
IN2012DN05169A (zh)
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
WO2012142515A3 (en) Fc fusion proteins comprising novel linkers or arrangements
SG162687A1 (en) Caustic stable chromatography ligands
CR20120371A (es) Antagonistas de pcsk9
EA201171148A1 (ru) Антитело-антагонист, специфичное для гетеродимера альфа-4-бета-7
BRPI0813452A2 (pt) protéinas de fusão rage.
WO2011047087A3 (en) Protein detection via nanoreporters
WO2012139134A3 (en) Methods of modulating oncogenic fusion proteins
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
MX2010000196A (es) Prevencion de reduccion de enlaces de disulfuro durante la produccion recombinante de polipeptidos.
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
EP2516624A4 (en) CELL LINE 3M
WO2008033408A3 (en) Methods for identifying compounds that modulate cell signaling and methods employing such compounds
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
MX2010007716A (es) Combinacion de una proteina de fusion del anticuerpo-il-2 de anti-edb fibronectina y una molecula que se une a celulas b, progenitores de la celula b y/o sus contrapartes cancerigenas.
TR201911082T4 (tr) K vitaminine bağımlı proteinlerin saflaştırılması için bir işlem.
BRPI1016204A2 (pt) proteínas de fusão de anticorpos com sítios de ligação fcrn modificados
WO2013052946A3 (en) Genetically encoded biosensors
IN2012DN02073A (zh)
WO2008085900A3 (en) Methods for generating novel stabilized proteins
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
EP3976642A4 (en) APOE ANTIBODIES, FUSION PROTEINS AND THEIR USES
EA201691532A1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
WO2014150748A3 (en) Stabilized single human cd4 domains and fusion proteins